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Objective To evaluate the seroprevalence of Chlamydia pneumoniae and age, gender and
smoking habits in stable asthmatic patients.
Methods Over a period of 3 months, 197 adult patients affected by intermittent-to-severe
chronic asthma were enrolled from 16 respiratory disease units in the south of Italy. As a
control group, we tested 185 healthy, non-asthmatic subjects matched for age and gender,
recruited among hospital staff. All patients were submitted to clinical examination,
spirometry and blood collection for C. pneumoniae serology. The presence of infection was
investigated by microimmunofluorescence (Micro-IF Test) for C. pneumoniae-specific IgG,
IgM and IgA antibodies.
Results C. pneumoniae IgG titers 1 : 64 were detected in 30.4% of asthmatics and in
30.8% of controls. Correlation of age, gender and smoking habit with C. pneumoniae
seropositivity was evaluated by linear regression analysis. Age was significantly asso-
ciated with C. pneumoniae IgG titer 1 : 64 when seropositive asthmatics were tested.
Moreover, C. pneumoniae seroprevalence was higher among smokers with a diagnosis of
chronic asthma.
Conclusions The seroprevalence of C. pneumoniae in stable asthmatics was comparable
with the controls; therefore, the study does not support the association between C.
pneumoniae antibody titers and stable asthma. However, the analysis for likely con-
founders such as age, gender and smoking status suggests a possible association of
enhanced susceptibility to C. pneumoniae infection with age and smoking habitus.
Keywords Micro-IF Test, chronic asthma, Chlamydia pneumoniae, seroprevalence
Accepted 21 December 2001
Clin Microbiol Infect 2002; 8: 358–362
I N T R O D U C T I O N
Chlamydia pneumoniae is an intracellular pathogen
recognized as being responsible for respiratory
tract infection [1]. For the clinician, the diagnosis
of C. pneumoniae infection may be difficult because
of the lack of widespread availability of diagnostic
facilities for either organism identification or ser-
ologic testing and because of controversies sur-
rounding serodiagnostic criteria [2]. A serologic
method for the diagnosis of C. pneumoniae infection
based on microimmunofluorescence (Micro-IF
Test) has been introduced for both the laboratory
and clinical setting [1]. A four-fold rise in the IgG
titer, an IgM titer 1 : 16 or greater, or an IgG titer
1 : 512 have been considered to be consistent with
acute infection [3]. IgG titers >1 : 16 and <1 : 512
are considered to be evidence of prior infection but
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Corresponding author and reprint requests: G. Miragliotta,
Section of Microbiology, University of Bari, P.zza G. Cesare,
11, 70124 Bari, Italy
Tel: þ39 080 5478486
Fax: þ39 080 5478486
E-mail: miragliotta@midim.uniba.it
not necessarily of recent infection [4]. Serologic
markers of C. pneumoniae infection have also
shown a significant association with asthma [5].
With regard to a possible difference in terms of C.
pneumoniae antibody seroprevalence between asth-
matic subjects and the normal population, there
are conflicting results [6–12]. The association of C.
pneumoniae seroprevalence with age and gender
has also been investigated. Age-specific preva-
lence is low in pre-school children, intermediate
during the school-age years, and increases pro-
gressively over the years, up to 40–60% in the 4th
to 6th decades of life, and thereafter remaining
constant [13]. Furthermore, the association
between smoking habit and seroconversion to C.
pneumoniae has also been described [14,15]. How-
ever, up to now, the role of C. pneumoniae infection
in the development of asthma is not adequately
established. Our study aimed to investigate the
seroprevalence of C. pneumoniae infection in a
group of clinically stable asthmatics in comparison
with a control group of healthy subjects. In addi-
tion, the association of some demographic and
clinical variables with C. pneumoniae infection
has been evaluated.
M A T E R I A L S A N D M E T H O D S
Study population
One hundred and ninety-seven adult patients (89
male, 108 female, aged 14–78 years, mean age
39.9 15.4) affected by intermittent-to-severe
chronic asthma were enrolled from 16 respiratory
disease units in the south of Italy. All patients were
admitted consecutively throughout a 3-month per-
iod (April to June 1998): 27 of 197 (13.70%) patients
were current smokers. The criteria for inclusion
were a stable condition of asthma, no acute infec-
tion or variation of therapy for at least 1 month,
and treatment for asthma according to guidelines
[16].
According to the NHLBI/WHO criteria, 71 of
182 (39%) patients were classified as affected by
intermittent, 52 of 182 (28.5%) by mild, 42 of 182
(23%) by moderate, and 17 of 182 (9.3%) by severe
asthma.
A non-asthmatic control group of 185 healthy
subjects (65 male, 89 female, aged 16–77 years,
mean age 35.8 13.4) matched for age, gender
and race were studied at the same time. They were
recruited among students, medical doctors and
hospital workers, without clinical evidence of C.
pneumoniae infection. All the control subjects were
normal when studied for pulmonary functions.
Fifty of 185 (27.02%) subjects were current smo-
kers.
Study design
All patients were submitted to clinical examina-
tion, spirometry and blood collection for C. pneu-
moniae serology. Control subjects underwent only
a blood collection for C. pneumoniae serology. In the
presence of a significant antibody titer, a second
blood sample was drawn after 3 weeks and
screened for any rise in the titer. The study was
approved by the local ethical committee, and all
subjects gave informed consent. All data were
collected and entered into a computerized data-
base.
Microimmunofluorescence test
A Micro-IF test was used to measure IgM, IgG and
IgA antibodies against C. pneumoniae, using C.
pneumoniae elementary bodies as antigen (C. pneu-
moniae IgG/IgM Micro-IF test Kit, and C. pneumo-
niae IgA Micro-IF test Kit, LabSystems, Helsinki,
Finland).
For each subject (both asthmatic and control), a
sample of 4 mL of serum was divided into two
aliquots and stored at 20 8C until processing. All
sera were screened at a dilution of 1 : 16 for IgM,
1 : 32 for IgA, and 1 : 64 for IgG. Positive samples
were tested at dilutions up to 1 : 1024. According to
the manufacturer’s instructions, antibody titers
were considered positive at the following values:
IgG 1 : 64, IgM 1 : 16, and IgA 1 : 32. In the
absence of IgM, a titer of IgG >1 : 64< 1 : 512 was
considered to be indicative of previous exposure
[4].
All serologic tests were carried out by the same
biologist at ‘S. Maugeri’ Foundation laboratory,
Cassano Murge, Bari. At random, 40 serologic tests
were performed in parallel at the laboratory of the
Institute of Respiratory Disease, University of
Milan, Milan, Italy (data not shown).
Statistical analysis
The seroprevalence of C. pneumoniae infection was
compared in patients and controls by chi-square
test of Pearson.
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Logistic regression modeling, as implemented
in the SAS Institute Inc., Cary, NC, USA, was used
to evaluate the correlation of IgG antibody titer to
C. pneumoniae with age, gender, smoking habits,
severity of asthma, and duration of the disease
(P< 0.05). All variables described above were
included as covariates: a stepwise process was
used to identify a reduced model which used only
variables where P< 0.1.
R E S U L T S
No significant difference in the prevalence of pre-
vious infection (IgG 16) was found between asth-
matics and controls (30.4% versus 30.8%)
(P¼ 0.37). In only two asthmatics was a C. pneu-
moniae antibody titer indicative of acute C. pneu-
moniae reinfection (IgG¼ 1 : 512) detected, but
neither clinical nor functional parameters con-
firmed the diagnosis. Comparable seroprevalences
of previous infection (IgG >1 : 64< 1 : 512) with
IgA association were found between asthmatics
and controls (2% versus 3.8%), with no acceptable
explanation for the higher prevalence in controls.
One healthy subject with a detectable IgM titer was
not investigated further and was excluded from
the study (Table 1).
The characteristics of asthmatics with IgG
1 : 64 and asthmatics with IgG <1 : 64 are shown
in Table 2.
In order to define within the group of asthmatics
the possible association of independent factors (i.e.
age, gender, smoking habits, severity and duration
of asthma) with IgG titers 1 : 64, we applied a
logistic regression analysis. Results show that
smoking habits and age were the strongest factors
associated with C. pneumoniae antibodies (Table 3).
D I S C U S S I O N
Our serologic study on a group of asthmatic sub-
jects showed that 30.4% of them had a C. pneumo-
niae IgG titer 1 : 16< 1 : 512, which is consistent
with a prior infection, while only 1% exhibited an
IgG titer of 1 : 512, which may be related to an acute
infection [3]. The putative role of C. pneumoniae in
the development of wheezing and asthma in adult
subjects has been suggested. In particular, the
association between C. pneumoniae infection and
asthma has been previously described in patients
who developed asthma after a lower respiratory
tract infection due to C. pneumoniae [6], and, sub-
sequently, C. pneumoniae seropositivity was
demonstrated to be significantly related to wheez-
ing and asthma in adults [17]. An antibody titer
consistent with previous C. pneumoniae infection
(IgG 1 : 64–1 : 256) was detected in 14.6% of the
patients with acute asthma, and in 34.8% of the
patients with severe chronic asthma [11]. These
data allow us to speculate that chronic C. pneumo-
niae infection may play an important role in the
development of severe chronic asthma. On the
other hand, increased production of IL-1, IL-6,
TNF-a and granulocyte macrophage-colony
Table 1 C. pneumoniae serology (immunoglobulin titers) in








IgG 1 : 64< 1 : 512
(negative IgA)
60 (30.4) 57 (30.8)
IgG¼ 1 : 512 2 (1) 0
IgG 1 : 64þ IgA 1 : 32 4 (2) 7 (3.8)
IgA 1 : 32 (IgG< 1 : 64) 2 (1.0) 0 (0)
IgM 1 : 16 0 1
No. of total subjects studied: a197; b185.
Table 2 Characteristics of asthmatic patients
IgG> 1 : 64 IgG< 1 : 64
N 64 133
Age (years) 43.0 (16.4) 38.4 (14.7)
Male/female 31/33 59/74
Smokers 8 19






Table 3 Logistic regression comparing asthmatics with
IgG 1 : 64 and with IgG <1 : 64
Adjusted
odds ratio 95% CI P
Age 1.01 1.00–1.04 0.23
Gender 0.85 0.44–1.65 0.63
Smoking 0.57 0.30–1.04 0.07
Severity of asthma 0.1 0.71–1.36 0.95
Duration of disease 1 0.98–1.04 0.51
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stimulating factor (GM-CSF) has been demon-
strated in bronchial epithelial cells infected with
C. pneumoniae [18]. The increased production of
these proinflammatory cytokines could influence
the severity of the disease through the persistent or
recurrent inflammation of the airways, leading to
the progression of mild asthma to the chronic
disease. Furthermore, chronic C. pneumoniae infec-
tion, acting as a cofactor, might make the subject
more susceptible to other stimuli such as viruses or
allergens or both.
Our results show that the seroprevalence in
stable asthmatics is comparable with that of the
controls, without any significant difference
between the two groups (30.4% versus 30.8%).
This finding is in agreement with the work of
different authors. Weiss et al. [9] reported compar-
able levels of C. pneumoniae IgG titers 1 : 16 in
subjects with bronchospasm and in asymptomatic
controls. Hahn et al. [10] observed a C. pneumoniae
IgG titer 116 in 92% of 25 patients with recent-
onset asthma and in 84% of 45 asymptomatic
controls. Larsen et al. [19] found a similar C.
pneumoniae seroprevalence in 22 adult asthmatics
and in 25 healthy controls (22% versus 24%). In our
study, the lack of difference in C. pneumoniae
seroprevalence between patients with stable
chronic asthma and healthy controls could be
explained by the presence of potential confounder
factors in both asthmatics and controls, such as a
low mean age and the occupational status. In fact,
the study population (asthmatics and controls)
matched for age presented a mean age <40 years.
In addition, the occupational status can be con-
sidered to be a confounder factor, since the con-
trols had been recruited among hospital staff and
therefore might be more susceptible to respiratory
tract infections.
The constant presence of short-lived IgA anti-
bodies has been proposed to indicate chronic
infection, whereas stable elevated levels of more
long-lived IgG antibodies may reflect recurrent
infections in the past. We found only two asth-
matic patients with a significant IgA titer. This
could be explained by the consideration that our
patients were in a clinically stable condition.
The study by Black et al. [20] showed the asso-
ciation of the severity of asthma and the mean IgG
and IgA titers with C. pneumoniae infection. How-
ever, they found the higher titers of antibodies to
C. pneumoniae in subjects on treatment with high-
dose inhaled corticosteroids. Our data do not
support the association between severity and
duration of asthma with C. pneumoniae seropreva-
lence.
Within the group of asthmatics, we found that
age was related to the Ig G titer 1 : 64. Further-
more, the logistic regression analysis showed that
C. pneumoniae seroprevalence was higher among
smokers with a diagnosis of chronic asthma.
Smoke might act as a proinflammatory factor
and might induce bronchial hyperresponsiveness
in asthmatic subjects, causing bronchoconstriction.
Previous studies of C. pneumoniae infection have
addressed the smoking habits of the patients. In
general, smokers have a higher risk of respiratory
infection than non-smokers [14]. Hahn et al. [21]
also found that smokers may be susceptible to C.
pneumoniae infection. A great propensity among
smokers to acquire C. pneumoniae infection might
suggest a close association between smoking and
seroconversion to C. pneumoniae as detected by
microimmunofluorescence [15].
Although the difference in C. pneumoniae sero-
prevalence between asthmatics and the control
group is not statistically significant, taken together
our data raise important questions about the asso-
ciation of C. pneumoniae infection with chronic
asthma which should be further clarified.
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